Hence, on disrupting TP53 function within an AML cell line by using CRISPR/Cas9, DiNardo et al. were able to demonstrate an association between TP53 loss and resistance to VEN, hypomethylating agent (HMA) and cytarabine (ARA-C) as a single agent or in combination [134]. The gene discussed is TP53; the disease is acute myeloid leukemia.